Type 2 Diabetes and MAFLD: Why Every Diabetic Patient Needs Liver Assessment | Elastography Australia
Type 2 diabetes and MAFLD overlap in up to two-thirds of cases. Here's the evidence-based screening pathway for Australian GPs managing diabetic patients with liver risk.
Of all the comorbidities associated with MAFLD, type 2 diabetes (T2DM) is the most clinically significant — and the most common. The overlap between these two conditions is not incidental; they share the same root cause in metabolic dysfunction, and each accelerates the other.
For the approximately 1.3 million Australians diagnosed with type 2 diabetes, liver fibrosis screening is no longer optional — it's part of evidence-based metabolic management.
How Common Is the Overlap?
The MAESTRO-NASH Phase 3 trial — the pivotal study behind resmetirom's FDA approval — enrolled over 966 MASH patients. Roughly two-thirds had type 2 diabetes. This mirrors real-world data consistently: T2DM prevalence in clinical MASH cohorts typically runs 40–70%, compared to the general population rate of approximately 5–6%.
Conversely, studies in T2DM populations find MAFLD prevalence of 60–80%. The AusDiab study found that 22% of Australians with diabetes had elevated ALT — a common surrogate marker for liver disease — compared to around 13% of the general cohort.
The clinical reality is simple: if your patient has type 2 diabetes, the probability that they also have MAFLD — and potentially significant fibrosis — is high enough to warrant systematic assessment.
Why Standard T2DM Monitoring Misses Liver Disease
Standard diabetes review in Australian primary care focuses on HbA1c, lipid profile, renal function, and cardiovascular risk. Liver-specific assessment is often not included unless the patient has obviously abnormal LFTs.
This creates a systematic gap. MAFLD can progress to advanced fibrosis with normal or mildly elevated liver enzymes. A patient with T2DM, a normal ALT, and a BMI of 32 may have F2 or F3 fibrosis — completely invisible to standard metabolic monitoring.
The GESA MAFLD Consensus Statement (2025) recommends that MAFLD should be considered in all patients with T2DM or two or more metabolic risk factors — explicitly positioning this as a primary care responsibility.
The Screening Pathway for T2DM Patients
Australian clinical guidance recommends a stepwise approach:
1. Identify risk: any T2DM patient is at elevated risk. Additional risk factors (obesity, hypertriglyceridaemia, hypertension) increase the probability of significant fibrosis.
2. Calculate FIB-4: from routine blood results (age, AST, ALT, platelet count). FIB-4 <1.3 = low risk, can monitor annually. FIB-4 >2.67 = high risk, refer for hepatology assessment.
3. Indeterminate FIB-4 (1.3–2.67): order liver elastography. This is the step that currently creates the largest bottleneck in the clinical pathway — referral wait times can extend 3–6 months in busy tertiary centres.
4. Elastography result: interpret kPa against MAFLD thresholds. <8 kPa typically reassuring (low fibrosis risk), 8–12 kPa warrants monitoring and repeat elastography, >12 kPa warrants specialist referral.
For T2DM patients, the FIB-4 calculation is free — it uses blood results you already have. The bottleneck is the next step. In-house elastography removes that bottleneck entirely.
GLP-1 Agonists: What the Latest Data Shows
Many Australian GPs are now prescribing GLP-1 receptor agonists (semaglutide, dulaglutide) for their T2DM patients, partly because of weight loss benefits. An important question — particularly as resmetirom moves toward potential Australian availability — is whether GLP-1 use affects liver outcomes.
A 2025 secondary analysis of the MAESTRO-NASH trial published in Alimentary Pharmacology & Therapeutics found that resmetirom's efficacy in improving MASH and fibrosis was consistent regardless of whether patients were taking GLP-1 agonists or SGLT2 inhibitors. MASH resolution rates in patients on stable GLP-1 RA therapy reached 39% with resmetirom, closely mirroring the 38% response in patients not on GLP-1 agents.
This is clinically relevant because it suggests GLP-1 therapy does not substitute for — or interfere with — liver-specific fibrosis management. Your diabetic patient on semaglutide who also has MAFLD still needs liver fibrosis staging.
High-Risk Patient Identification in Practice
The following profile in your patient list warrants proactive FIB-4 calculation and subsequent elastography if indeterminate:
• T2DM with BMI >27 kg/m²
• T2DM with any of: ALT elevation, hypertriglyceridaemia, hypertension, or metabolic syndrome
• T2DM with known fatty liver on any prior imaging
• T2DM with unexplained fatigue or right upper quadrant discomfort
• T2DM age >50 — advancing age accelerates fibrosis progression in MAFLD
Generating this list from your practice's chronic disease register is a practical starting point. If your practice software supports it, a search for T2DM + BMI >27 + age >40 will identify the highest-yield cohort for systematic FIB-4 review.